Ignite Creation Date:
2024-10-26 @ 3:43 PM
Last Modification Date:
2024-10-26 @ 3:43 PM
Study NCT ID:
NCT06655324
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-10-21
Brief Title:
A Study to Evaluate Safety Tolerability and Immunogenicity of V350A and V350B in Healthy Participants V350-001
Sponsor:
None
Organization:
None
Study Overview
Official Title:
A Phase 1 Randomized Double-Blind Placebo-Controlled Dose Escalation Trial to Evaluate the Safety Tolerability and Immunogenicity of V350A and V350B in Healthy Participants
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Epstein Barr virus EBV is a virus which can cause infectious mononucleosis and is associated with certain kinds of cancer and multiple sclerosis Researchers are looking for new ways to prevent disease related to EBV and have developed a new study vaccine V350A and V350B The main goal of this study is to learn about the safety and tolerability of V350A and V350B in healthy adults
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None